Analysts predict that Supernus Pharmaceuticals (NASDAQ:SUPN) will post earnings per share of $0.33 for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Supernus Pharmaceuticals’ earnings. The highest EPS estimate is $0.45 and the lowest is $0.26. Supernus Pharmaceuticals posted earnings per share of $0.19 during the same quarter last year, which would indicate a positive year-over-year growth rate of 73.7%. The company is scheduled to report its next earnings results on Tuesday, May 8th.
According to Zacks, analysts expect that Supernus Pharmaceuticals will report full year earnings of $1.85 per share for the current year, with EPS estimates ranging from $1.76 to $1.98. For the next fiscal year, analysts forecast that the company will report earnings of $2.64 per share, with EPS estimates ranging from $2.31 to $3.05. Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that follow Supernus Pharmaceuticals.
Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.26 by $0.18. The firm had revenue of $88.44 million during the quarter, compared to analyst estimates of $87.84 million. Supernus Pharmaceuticals had a return on equity of 28.07% and a net margin of 18.95%.
In other news, VP Victor Vaughn sold 60,000 shares of the business’s stock in a transaction that occurred on Thursday, April 5th. The stock was sold at an average price of $45.33, for a total value of $2,719,800.00. Following the transaction, the vice president now owns 24,344 shares in the company, valued at approximately $1,103,513.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Padmanabh P. Bhatt sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $44.98, for a total value of $899,600.00. Following the completion of the transaction, the vice president now owns 32,500 shares in the company, valued at approximately $1,461,850. The disclosure for this sale can be found here. Insiders sold a total of 100,000 shares of company stock worth $4,580,200 in the last 90 days. Company insiders own 6.70% of the company’s stock.
Institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC bought a new stake in Supernus Pharmaceuticals during the 3rd quarter valued at $10,646,000. Stephens Investment Management Group LLC purchased a new stake in Supernus Pharmaceuticals during the fourth quarter valued at about $7,316,000. Wells Fargo & Company MN boosted its position in Supernus Pharmaceuticals by 22.7% during the fourth quarter. Wells Fargo & Company MN now owns 755,422 shares of the specialty pharmaceutical company’s stock valued at $30,105,000 after buying an additional 139,838 shares during the period. BlackRock Inc. boosted its position in Supernus Pharmaceuticals by 1.8% during the fourth quarter. BlackRock Inc. now owns 6,902,230 shares of the specialty pharmaceutical company’s stock valued at $275,054,000 after buying an additional 120,394 shares during the period. Finally, Rice Hall James & Associates LLC boosted its position in Supernus Pharmaceuticals by 8.0% during the fourth quarter. Rice Hall James & Associates LLC now owns 1,322,614 shares of the specialty pharmaceutical company’s stock valued at $52,706,000 after buying an additional 98,297 shares during the period. Institutional investors and hedge funds own 96.30% of the company’s stock.
SUPN traded down $0.80 during midday trading on Friday, reaching $45.25. 398,925 shares of the company were exchanged, compared to its average volume of 684,803. The firm has a market capitalization of $2,352.67, a P/E ratio of 35.91 and a beta of 1.11. Supernus Pharmaceuticals has a one year low of $29.95 and a one year high of $50.04.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.